Bio-Techne Q1 FY2026 revenue down 1% to $286.6M; adjusted EPS flat $0.42; declares $0.08 dividend

BIO-TECHNE Corp

2026-Q1 EPS reported $0.24 revenue$286,555,000

Revenue $286.6M (-1% YoY); GAAP EPS $0.24 (up from $0.21); adjusted EPS $0.42 (flat).
Protein Sciences segment rev $202.2M (-1% YoY); op margin 38.4% vs 39.4%.
Diagnostics & Spatial Biology rev $79.5M (-4%), organic +3%; op margin 11.2% vs 5.1% (benefited from Exosome divestiture).
Completed Exosome Diagnostics divestiture; CEO notes biotech funding headwinds but stability in US academic.
Declares quarterly dividend $0.08/share, payable Nov 28 to holders of record Nov 17.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.